secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2025-10-08T23:59:59+00:00
Accession:  0001193125-25-234516
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences raises $50M via stock and pre-funded warrants; BLA submission set for Q1 2026
--------------------------------------------------------------------------------

- Private placement: 502,181 shares at $68.00 and pre-funded warrants for 233,144 shares; gross proceeds ~$50M; closing expected Oct 9, 2025.
- Pre-funded warrants exercisable at $0.01 for 5 years, subject to 9.99% beneficial ownership limitation.
- Company to file resale registration statement within 20 days after closing.
- Pipeline update: TA-ERT for Sanfilippo Syndrome Type B BLA submission planned for Q1 2026; potential US commercial launch in late 2026.
- Placement agents: Leerink Partners, Citizens Capital Markets, H.C. Wainwright, Oppenheimer & Co.; 6% fee on gross proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000119312525234516/0001193125-25-234516-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000119312525234516/d36248d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-234516

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer